MaxCyte signs strategic platform license with Lyell Immunopharma

MaxCyte (MXCT) announced the signing of a strategic platform license, SPL, with Lyell Immunopharma (LYEL), a clinical stage T cell reprogramming company. Under the terms of the agreement, Lyell Immunopharma obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. In return, MaxCyte is eligible to receive platform licensing fees, clinical milestone payments and sales-based payments. “At MaxCyte, our goal is to maximize the potential of cells to improve patients’ lives, and it is through collaborations such as this that we can achieve success,” said Doug Doerfler, President and CEO of MaxCyte. “We look forward to supporting Lyell Immunopharma in its development of solid tumor treatments for patients with unmet needs.”